Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Program Official
Principal Investigator
Seema Harichand
Awardee Organization

Iowa Oncology Research Association
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Iowa-Wide Oncology Research Coalition (I-WORC)

The Iowa-Wide Oncology Research Coalition (I-WORC) is a multidisciplinary consortium of nineteen components and six sub-component performance sites comprised of twelve hospitals, including one designated children’s hospital, nine gynecologic, medical, pediatric, radiation, and surgical oncology practices and sixty-five physician investigators. In addition to the operations office in Des Moines, the I-WORC has component sites located in four geographical regions in Iowa (Ames, Cedar Rapids, Mason City and Ottumwa/Fairfield) and one geographical region in Moline, Illinois. I-WORC is an original NCI Community Oncology Research Program (NCORP) Community Site and has affiliations with the following research bases: Alliance, ECOG-ACRIN, NRG, Wake Forest, and COG. I-WORC also actively participates in other non-member research base studies through the Cancer Trials Support Unit (CTSU) and has experience using the Central Investigational Review Board (CIRB) for human subjects review. The goals of I-WORC are: 1) Provide excellence in cancer care to patients and families through participation in high quality cancer research studies including control, prevention, treatment and care delivery; 2) Support the goals and work of research bases with involvement of I-WORC investigators and research staff to provide insight into clinical significance and feasibility during concept and protocol development, as well as identification of unique patient populations; 3) Increase public and professional awareness of clinical trials through community outreach efforts and collaboration with other medical providers in the community; 4) Increase accrual in clinical studies by building on prior recruitment strategies implemented in previous cancer control/cancer prevention, precision medicine, and treatment studies; 5) Develop strategies to increase clinical trial participation that contributes to overall representativeness of NCI clinical trials; 6) Collaborate with local health care institutions to increase participation in correlative and translational bio-specimen collection studies; 7) Collaborate with local health care institutions to continue to develop and expand participation in cancer care delivery studies; 8) Capture and document screening efforts for clinical trial enrollment and address cancer health outcomes by building on prior screening log strategies.

Publications

  • Bradbury AR, Lee JW, Gaieski JB, Li S, Gareen IF, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ, Nambudiri GS, Carlos RC, Wagner LI. A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). Cancer. 2022 Apr 1;128(7):1381-1391. Epub 2021 Dec 10. PMID: 34890045